1 / 8

Hepatitis Therapeutics Market Variables, Trends& Scope Till 2025

The global hepatitis therapeutics market size was valued at USD 19.56 billion in 2016.The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs.

adamhurdle023
Télécharger la présentation

Hepatitis Therapeutics Market Variables, Trends& Scope Till 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis Therapeutics Market Value is to be $25.8 Billion By 2025 “The global hepatitis therapeutics market size was valued at USD 19.56 billion in 2016.The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs” The global Hepatitis Therapeutics Market is expected to reach USD 25.8 billion by 2025 according to a new report by Grand View Research, Inc. The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines. Access Full Research Report on Global Hepatitis Therapeutics Market : http://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics- market Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected Follow Us:

  2. sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions. According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions. Further key findings from the study suggest: Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016 In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure. Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate. Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc. Grand View Research has segmented the global Hepatitis Therapeutics Market on the disease type, and region: Read Our Blogs on Reports from this category By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare Table of Content of Global Hepatitis Therapeutics Market Research Report: Follow Us:

  3. Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data Sources Chapter 2. Executive Summary 2.1. Market Snapshot Chapter 3. Hepatitis Therapeutics Market Variables, Trends& Scope 3.1. Market Segmentation 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.2. Market restraint analysis 3.3. Key Opportunities Prioritized 3.4. Industry Analysis - Porter's 3.5. Hepatitis Therapeutics Market-SWOT Analysis, By Factor (political & legal, economic and technological), 2015 Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis 4.1. Hepatitis Therapeutics Market Share by Disease Type, 2015 & 2025 (USD Million) 4.2. Hepatitis A 4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million) 4.3. Hepatitis B 4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 4.4. Hepatitis C 4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million) 4.5. Others 4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million) Follow Us:

  4. Chapter 5. Hepatitis Therapeutics Market: Regional Outlook 5.1. Hepatitis Therapeutics Market share by region, 2015 & 2025 (USD Million) 5.2. North America 5.2.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.2.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.2.3. U.S. 5.2.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.2.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.2.4. Canada 5.2.4.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.2.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.3. Europe 5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.3.3. Germany 5.3.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.3.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.3.4. UK 5.3.4.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.3.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) Follow Us:

  5. 5.4. Asia Pacific 5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.4.3. China 5.4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.4.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.4.4. Japan 5.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.4.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.5. Latin America 5.5.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.5.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.5.3. Brazil 5.5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.5.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.5.4. Mexico 5.5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.5.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) 5.6. Middle East & Africa 5.6.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.6.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Follow Us:

  6. Million) 5.6.3. South Africa 5.6.3.1. Market estimates and forecast, 2014 - 2025 (USD Million) 5.6.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million) Chapter 6. Competitive Landscape 6.1. Strategic Framework 6.2. Gilead Lifesciences 6.2.1. Company overview 6.2.2. Financial performance 6.2.3. Product benchmarking 6.2.4. Strategic initiatives 6.3. Bristol-Myers Squibb Co 6.3.1. Company overview 6.3.2. Financial performance 6.3.3. Product benchmarking 6.3.4. Strategic initiatives 6.4. Biocon 6.4.1. Company overview 6.4.2. Financial performance 6.4.3. Product benchmarking 6.4.4. Strategic initiatives 6.5. AbbVie 6.5.1. Company overview 6.5.2. Financial performance 6.5.3. Product benchmarking 6.5.4. Strategic initiatives Follow Us:

  7. 6.6. Merck & Co., Inc., 6.6.1. Company overview 6.6.2. Financial performance 6.6.3. Product benchmarking 6.6.4. Strategic initiatives 6.7. Johnson & Johnson 6.7.1. Company overview 6.7.2. Financial performance 6.7.3. Product benchmarking 6.7.4. Strategic initiatives About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Follow Us:

  8. Email:sales@grandviewresearch.com For More Information:http://www.grandviewresearch.com Follow Us:

More Related